[Activity of creatine kinase and its isoenzymes in hemolytic uremic syndrome].
Serum creatine kinase (CK) and CK isoenzymes (CK-MM, CK-MB and CK-BB) were measured in 35 healthy and 25 children with hemolytic uremic syndrome (HUS) at 48 h, 7 and 15 days after admittance. Total serum CK activity was measured with a commercially available kit ("CK-NAC", by Merck, cat 14327) and CK isoenzymes using the Helena laboratories method. The interassay coefficients of variation with these methods are the following: for the total CK activity, 10.95 and 9.15% for an enzyme activity of 42 and 142 U/L respectively; for the activity of the isoenzymes, 6.8, 8.0 and 15.1% for activities of 102, 67 and 30 U/L. Total CK activity at 48 h in HUS patients defined two groups, group 1 (G1) which is not different from the control group (CG) and group 2 (G2) which had a significantly higher activity, p less than 0.0005. The increase in total CK remained significant until the first week. Increase in total CK resulted from the increase in CK isoenzymes: CK-MM, CK-MB and CK-BB. Highly significant correlation coefficients (p less than 0.0005) were obtained between total CK and their isoenzymes. When we examined both groups of patients in relation to clinical parameters, no difference could be found although G2 showed higher urea and fibrinogen degradation products with significantly decreased platelet counts. Although the reasons for enzyme release are not understood, anoxia and chemical toxins have been incriminates.(ABSTRACT TRUNCATED AT 250 WORDS)
Ramírez
J
J
Zgaib
S
S
de Miguel
R
R
Ferraris
J
J
Pérsico
R
R
da Graca
I Z
IZ
Gianantonio
C
C
D000704:Analysis of Variance; D002675:Child, Preschool; D003402:Creatine Kinase / Q000378:metabolism*; D004588:Electrophoresis, Cellulose Acetate; D006463:Hemolytic-Uremic Syndrome / Q000201:enzymology*; D006801:Humans; D007223:Infant; D007527:Isoenzymes; D009132:Muscles / Q000201:enzymology*; D014508:Urea / Q000097:blood
D007527:Isoenzymes; D014508:Urea; D003402:Creatine Kinase
Actividad de la creatina kinasa y sus isoenzimas en el síndrome urémico hemolítico.